
C the Signs
Using AI to help healthcare professionals detect cancer early and streamline referral pathways across health systems.
Date | Investors | Amount | Round |
---|---|---|---|
- | investor | €0.0 | round |
investor | €0.0 | round | |
investor | €0.0 | round | |
investor | €0.0 | round | |
investor investor investor | €0.0 | round | |
investor | €0.0 | round | |
* | $8.0m | Early VC | |
Total Funding | 000k |
USD | 2022 | 2023 |
---|---|---|
Revenues | 0000 | 0000 |
% growth | - | 8 % |
EBITDA | 0000 | 0000 |
Profit | 0000 | 0000 |
EV | 0000 | 0000 |
EV / revenue | 00.0x | 00.0x |
EV / EBITDA | 00.0x | 00.0x |
R&D budget | 0000 | 0000 |
Source: Dealroom estimates
Related Content
C the Signs is a healthtech company using artificial intelligence to help healthcare professionals detect cancer at the earliest possible stage, when treatment is most effective. The platform supports clinicians by analyzing patient symptoms, clinical data, and risk factors in real time to recommend appropriate diagnostic and referral pathways. Designed to integrate into primary care and wider health system workflows, C the Signs bridges the gap between complex cancer guidelines and practical clinical decision-making. The tool is particularly valuable in supporting earlier diagnosis across all cancer types, including rare and hard-to-detect cancers. It improves patient outcomes by enabling faster referrals, reducing diagnostic delays, and supporting more personalized care. With a strong focus on population health, the platform also helps healthcare systems identify disparities in care access, streamline operational efficiency, and align with national cancer targets. C the Signs is trusted by healthcare providers and systems in the UK and internationally, playing a crucial role in transforming how cancer is diagnosed and managed at scale.
Keywords:
C the Signs, early cancer detection, AI healthcare platform, clinical decision support, digital health, oncology diagnostics, healthtech, cancer referral system, primary care integration, cancer risk assessment, personalized medicine, NHS, healthcare innovation, population health, diagnostic tools.